Rapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 20,225 Shares of Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) insider Krishnaswamy Yeleswaram sold 20,225 shares of the firm’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $39.99, for a total value of $808,797.75. Following the completion of the sale, the insider owned 246,426 shares in the company, valued at $9,854,575.74. The trade was a 7.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Krishnaswamy Yeleswaram also recently made the following trade(s):

• On Tuesday, April 14th, Krishnaswamy Yeleswaram sold 10,200 shares of Rapport Therapeutics stock. The shares were sold at an average price of $35.08, for a total value of $357,816.00.
• On Monday, April 13th, Krishnaswamy Yeleswaram sold 9,165 shares of Rapport Therapeutics stock. The shares were sold at an average price of $34.97, for a total value of $320,500.05.
• On Friday, April 10th, Krishnaswamy Yeleswaram sold 500 shares of Rapport Therapeutics stock. The shares were sold at an average price of $34.98, for a total value of $17,490.00.
• On Wednesday, April 8th, Krishnaswamy Yeleswaram sold 360 shares of Rapport Therapeutics stock. The shares were sold at an average price of $34.90, for a total value of $12,564.00.

Rapport Therapeutics Stock Performance

RAPP stock opened at $36.95 on Wednesday. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of -12.92 and a beta of 1.09. Rapport Therapeutics, Inc. has a 1 year low of $7.73 and a 1 year high of $42.27. The stock’s fifty day moving average is $30.70 and its two-hundred day moving average is $28.68.

Rapport Therapeutics (NASDAQ:RAPP) last posted its earnings results on Tuesday, March 10th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.07). As a group, analysts predict that Rapport Therapeutics, Inc. will post -3.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Rapport Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Strs Ohio raised its position in Rapport Therapeutics by 23.5% in the third quarter. Strs Ohio now owns 2,100 shares of the company’s stock worth $62,000 after acquiring an additional 400 shares in the last quarter. Russell Investments Group Ltd. raised its position in Rapport Therapeutics by 56.9% in the fourth quarter. Russell Investments Group Ltd. now owns 2,282 shares of the company’s stock worth $69,000 after acquiring an additional 828 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Rapport Therapeutics by 64.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company’s stock worth $70,000 after acquiring an additional 905 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Rapport Therapeutics in the fourth quarter worth about $37,000. Finally, Creative Planning raised its position in Rapport Therapeutics by 12.8% in the third quarter. Creative Planning now owns 11,959 shares of the company’s stock worth $355,000 after acquiring an additional 1,357 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Wells Fargo & Company lifted their price objective on shares of Rapport Therapeutics from $43.00 to $46.00 and gave the company an “overweight” rating in a research note on Wednesday, March 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Thursday, January 22nd. Truist Financial upgraded shares of Rapport Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. TD Cowen restated a “buy” rating on shares of Rapport Therapeutics in a research note on Monday, March 9th. Finally, Raymond James Financial assumed coverage on shares of Rapport Therapeutics in a research note on Friday, April 10th. They set a “strong-buy” rating and a $66.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Rapport Therapeutics currently has an average rating of “Buy” and a consensus price target of $53.83.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.